DW 1001
Alternative Names: DW-1001Latest Information Update: 03 Aug 2022
At a glance
- Originator Unknown
- Developer D. Western Therapeutics Institute; Rohto Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Eye disorders
Most Recent Events
- 14 Jul 2022 DW 1001 licensed to ROHTO Pharmaceutical (DWTI pipeline-July 2022)
- 01 Mar 2022 Phase-I clinical trials in Eye disorders in Japan (unspecified route) (DWTI pipeline-July 2022)
- 28 Feb 2022 Preclinical trials in Eye disorders in Japan (unspecified route) (Before March 2022) (DWTI pipeline-July 2022)